Table 3.

DAA therapy and viral monitoring

Survey QuestionResponse, n (%)
If you accept kidneys from donors who are HCV Ab+/NAT+ for recipients who are HCV−, when do you typically start DAA therapy? (item denominator=72a)
 Before transplant (on admission or en route)5 (7)
 After transplant, but before discharge10 (14)
 After discharge, but within 4 wk10 (14)
 After discharge, only if HCV viremic38 (53)
 Other9 (13)
If you accept kidneys from donors who are HCV Ab+/NAT+ for recipients who are HCV−, how long do you believe it is safe to wait to start DAA therapy? (item denominator=68a)
 At time of transplant6 (9)
 After transplant, but before discharge8 (12)
 After discharge but within 2 wk, regardless of HCV viremia6 (9)
 After discharge but within 4 wk, regardless of HCV viremia11 (16)
 After discharge but only if HCV viremic32 (47)
 Other5 (7)
How often would you test a recipient of HCV Ab+/NAT+ donor kidney for HCV RNA after transplantation and appropriate 12 wk of DAA therapy? (item denominator=70a)
 Day 0, post-KTx day 1; DAA treatment weeks 1, 2, 3, 4, 8, and 12; after DAA treatment, continue testing at weeks 2, 4, 8, and 1213 (19)
 Day 0, post-KTx day 1; and at DAA treatment weeks 1, 2, 3, 4, 8, and 128 (11)
 Post-KTx day 1, weekly during DAA treatment for 12 wk7 (10)
 DAA treatment weeks 4, 8, and 1211 (16)
 DAA treatment weeks 4 and 126 (9)
 Post-KTx day 1 and at the end of 12 wk of DAA treatment1 (1)
 Other14 (20)
 Unsure10 (14)
If your program performs a transplant from a donor who is HCV Ab+/NAT+ into a recipient who is HCV− and the patient’s insurance declines DAA therapy, do you have an institutional plan to provide a complete course of medication? (item denominator=71a)
 No11 (15)
 Yes, from the transplant hospital40 (56)
 Yes, through a pharmaceutical company (e.g., grant, research)4 (6)
 Yes, through organ procurement organization0 (0)
 Yes, through the department of surgery or department of medicine2 (3)
 Other11 (15)
 Unsure3 (4)
  • Programs that reported not conducting transplant from donors who were HCV Ab+/NAT+ were omitted. DAA, direct-acting antiviral agent; HCV, hepatitis C virus; Ab, antibody; NAT, nucleic acid testing; KTx, kidney transplant.

  • a Indicates the item denominator, based on number of respondents, and accounting for contingent responses.